HALOZYME Files 8-K on Operations & Financial Condition

TL;DR

**HALOZYME just filed an 8-K on its financial results, keep an eye on their performance.**

AI Summary

HALOZYME THERAPEUTICS, INC. filed an 8-K on January 17, 2024, to report on its Results of Operations and Financial Condition. This filing, under Commission File Number 001-32335, indicates that the company's Common Stock, with a $0.001 par value, is registered on The Nasdaq Stock Market LLC under the trading symbol HALO. This matters to investors because it provides an update on the company's financial health and operational performance, which can influence stock valuation and future investment decisions.

Why It Matters

This filing provides a mandatory update on HALOZYME THERAPEUTICS, INC.'s financial and operational status, offering transparency to investors about the company's performance and stability.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure of financial condition and operations, not indicating any immediate new risks or significant changes.

Analyst Insight

A smart investor would use this filing as a prompt to look for the actual detailed financial results that will follow this general disclosure, as this 8-K only states the topic of the report, not the specifics.

Key Numbers

• $0.001 — par value per share (par value of HALOZYME's Common Stock)

Key Players & Entities

• HALOZYME THERAPEUTICS, INC. (company) — the registrant filing the 8-K
• The Nasdaq Stock Market LLC (company) — the exchange where HALO's stock is registered
• $0.001 (dollar_amount) — par value of Common Stock

Forward-Looking Statements

• HALOZYME will likely provide more detailed financial figures in an upcoming quarterly or annual report. (HALOZYME THERAPEUTICS, INC.) — high confidence, target: Q1 2024 earnings report

FAQ

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value HALO The Nasdaq Stock Market
• $827 million — es 2023 Revenue will be in the range of $827 million to $832 million. The Company estimates
• $832 million — will be in the range of $827 million to $832 million. The Company estimates 2023 royalties
• $445 million — 2023 royalties will be in the range of $445 million to $450 million. The Company estimates
• $450 million — will be in the range of $445 million to $450 million. The Company estimates 2023 Net Income
• $292 million — 2023 Net Income will be in the range of $292 million to $297 million, 2023 EBITDA will be in
• $297 m — will be in the range of $292 million to $297 million, 2023 EBITDA will be in the range
• $435 million — on, 2023 EBITDA will be in the range of $435 million to $440 million and 2023 Adjusted EBITD
• $440 million — will be in the range of $435 million to $440 million and 2023 Adjusted EBITDA will be in the
• $425 million — Adjusted EBITDA will be in the range of $425 million to $430 million. The Company estimates
• $430 million — will be in the range of $425 million to $430 million. The Company estimates 2023 GAAP Dilut
• $2.18 — AAP Diluted EPS will be in the range of $2.18 to $2.21 and 2023 Non-GAAP Diluted EPS
• $2.21 — ed EPS will be in the range of $2.18 to $2.21 and 2023 Non-GAAP Diluted EPS will be i
• $2.77 — AAP Diluted EPS will be in the range of $2.77 to $2.80. Use of Non-GAAP Financial M
• $2.80 — ed EPS will be in the range of $2.77 to $2.80. Use of Non-GAAP Financial Measures

Filing Documents

• halo-20240117.htm (8-K) — 61KB
• 0001159036-24-000003.txt ( ) — 189KB
• halo-20240117.xsd (EX-101.SCH) — 2KB
• halo-20240117_lab.xml (EX-101.LAB) — 24KB
• halo-20240117_pre.xml (EX-101.PRE) — 12KB
• halo-20240117_htm.xml (XML) — 3KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On January 17, 2024, Halozyme Therapeutics, Inc., a Delaware corporation (the "Company") hosted a financial update call to provide information related to the Company's patent portfolio, 2024 financial guidance and long-term financial outlook (the "Financial Update"). The slides used by the Company in the Financial Update presentation included a summary of preliminary, unaudited estimates regarding the Company's financial results for the year ended December 31, 2023, which are also set forth below. The financial results presented below are preliminary, estimated, and unaudited. They are subject to the completion and finalization of the Company's financial and accounting close procedures. They reflect management's estimates based solely upon information available to management as of the date of the Financial Update presentation. Further information learned during the completion and finalization of these procedures may alter the final results. These preliminary estimates should not be considered a substitute for the financial information to be filed with the Securities and Exchange Commission on the Company's Form 10-K for the year ended December 31, 2023 once it becomes available. There is a possibility that the Company's financial results for the twelve months ended December 31, 2023 could vary materially from these preliminary estimates. Accordingly, you should not place undue reliance upon this preliminary information. Unaudited Preliminary Estimates of Results for the Twelve Months Ended December 31, 2023 The Company estimates 2023 Revenue will be in the range of $827 million to $832 million. The Company estimates 2023 royalties will be in the range of $445 million to $450 million. The Company estimates 2023 Net Income will be in the range of $292 million to $297 million, 2023 EBITDA will be in the range of $435 million to $440 million and 2023 Adjusted EBITDA will be in the range of $425 million to

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve numerous risks and uncertainties. The Company's actual results may differ from its beliefs, expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements are not historical in nature and can be identified by words such as "believe," "expect," "anticipate," "estimate," "preliminary," "project," "plan," "continue," "intend," "should," "would," "could," "goal," "objective," "will," "may," "seek" or similar expressions or their negative forms, or by references to strategy, plans, or intentions. Examples of forward-looking statements in this Current Report on Form 8-K include statements regarding the Company's preliminary estimates of financial results for the twelve months ended December 31, 2023. These forward-looking statements are based on the Company's current assumptions, expectations and beliefs are subject to numerous risks, including, among other things unexpected levels of revenues (including royalty and milestone revenue received from our collaboration partners and product sales), expenditures and costs, unexpected delays in the execution of the Company's planned platform expansion, unexpected results or delays in the growth of the Company's ENHANZE business (including as a result of unexpected conversion rates) or other proprietary product revenues, obtaining new co-formulation or proprietary intellectual property, or in the development, regulatory review or commercialization of our partners' ENHANZE products, unexpected delays in the Company's plans to develop and commercialize a high volume auto-injector, regulatory approval requirements, unexpected adverse events or patient outcomes and competitive conditions. T

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HALOZYME THERAPEUTICS, INC. January 17, 2024 By: /s/ Nicole LaBrosse Name: Nicole LaBrosse Title: Senior Vice President, Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR